

April 30, 2019

# CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8

NEWARK, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2019 and to provide a business update.

## Conference Call Details

To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13688866. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at <http://ir.cymbabay.com/events>.

## About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay's lead development candidate, seladelpar, is a potent, selective and orally active PPAR $\delta$  agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar (ENHANCE) in patients with PBC. Seladelpar received orphan designation from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for PBC. Seladelpar also received Breakthrough Therapy Designation from the FDA and Priority Medicine status from the EMA for PBC. CymaBay is also conducting a Phase 2b proof-of-concept study of seladelpar for patients with NASH.

For additional information about CymaBay visit [www.cymbabay.com](http://www.cymbabay.com).

## Contact:

Hans Vitzthum  
LifeSci Advisors, LLC  
212-915-2568  
[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)



Source: CymaBay Therapeutics, Inc.